Drug intelligence / Profile preview

AZB-101

Development stage: Preclinical
Lead developer: AZothBio
Modality: Small Molecules

Overview

AZB-101 is a preclinical **small-molecule selective allosteric inhibitor of tyrosine kinase 2** being developed by AZothBio for autoimmune and inflammatory diseases. The program is described as targeting the **JH2 pseudokinase allosteric domain of TYK2**, with the intended advantage of minimizing off-target inhibition of JAK1, JAK2, and JAK3 relative to less selective Janus kinase inhibitors. Public pipeline information indicates that AZB-101 is in early preclinical development, with some materials also referring to the candidate as **DN302075**.

Targets

TYK2 (Tyrosine kinase 2)

Beyond the preview

Go deeper on AZB-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZB-101.

Explore the full profile